Drug Patents owned by Glaxo Grp England

1. List of Incruse Ellipta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7498440 GLAXO GRP ENGLAND Muscarinic acetylcholine receptor antagonists
Apr, 2025

(2 years from now)

US7488827 GLAXO GRP ENGLAND Muscarinic acetylcholine receptor antagonists
Dec, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8309572 GLAXO GRP ENGLAND Muscarinic acetylcholine receptor antagonists
Apr, 2025

(2 years from now)

US8183257 GLAXO GRP ENGLAND Muscarinic acetylcholine receptor antagonists
Jul, 2025

(2 years from now)

US9333310 GLAXO GRP ENGLAND Medicament dispenser
Oct, 2027

(4 years from now)

US8113199 GLAXO GRP ENGLAND Counter for use with a medicament dispenser
Oct, 2027

(4 years from now)

US8161968 GLAXO GRP ENGLAND Medicament dispenser
Feb, 2028

(5 years from now)

US8201556 GLAXO GRP ENGLAND Medicament dispenser
Feb, 2029

(6 years from now)

US8534281 GLAXO GRP ENGLAND Manifold for use in medicament dispenser
Mar, 2030

(7 years from now)

US8746242 GLAXO GRP ENGLAND Medicament dispenser
Oct, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
M Jun 9, 2022

Drugs and Companies using UMECLIDINIUM BROMIDE ingredient

Market Authorisation Date: 30 April, 2014

Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.

Dosage: POWDER;INHALATION

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic